M&A Deal Summary |
|
|---|---|
| Date | 2016-06-23 |
| Target | Oragenics - Consumer Probiotic Business |
| Sector | Life Science |
| Buyer(s) | ProBiora Health |
| Sellers(s) | Oragenics |
| Deal Type | Divestiture |
| Deal Value | 2M USD |
SEARCH BY
ProBiora Health LLC is a developer of antibiotics against infectious diseases.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 5 |
| Revenue | 14M USD (2022) |
Oragenics is a developer of of novel antibiotics against infectious disease and developing effective treatments for oral mucositis. Oragenics was founded in 1996 and is based in Tampa, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-04 |
Noachis Terra
United States Noachis Terra, Inc. develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (“SARS-CoV-2”), the root cause of coronavirus disease 2019 (“COVID-19”). |
Buy | $2M |
